Real-world effectiveness of fulvestrant monotherapy as first endocrine treatment in patients with metastatic breast cancer
{{output}}
Fulvestrant monotherapy is approved for postmenopausal women with hormone receptor-positive, metastatic breast cancer (MBC) who progressed following antiendocrine therapy, or those with hormone receptor-positive, human epidermal receptor 2-negative advanced br... ...
